Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.55 |
| ▸ | TDO2 | P48775 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.53 |
| ▸ | GABRP | O00591 | 2/20 | 0.53 |
| ▸ | GABRD | O14764 | 2/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.53 |
| ▸ | GABRE | P78334 | 2/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832015 | 1.00 | KIF11 (0.55) | KIF11TDO2KDM4EMAPTGABRA1 | |
| SCHEMBL25298405 | 0.95 | KDM4E (0.55) | KIF11TDO2KDM4EMAPTGABRA1 | |
| SCHEMBL31682284 | 0.95 | KDM4E (0.55) | KIF11TDO2KDM4EMAPTGABRA1 | |
| SCHEMBL27842256 | 0.89 | KIF11 (0.45) | KIF11TDO2KDM4EMAPTGABRA1 | |
| SCHEMBL27884581 | 0.88 | KIF11 (0.44) | KIF11TDO2KDM4EMAPTGABRA1 | |
| SCHEMBL21382671 | 0.87 | KIF11 (0.43) | KIF11TDO2KDM4EMAPTGABRA1 | |
| SCHEMBL26675637 | 0.84 | PARP1 (0.51) | KIF11KDM4EMAPTGABRA1GABRG2 | |
| SCHEMBL28533079 | 0.83 | TDO2 (0.40) | KIF11TDO2KDM4EMAPTGABRA1 | |
| SCHEMBL170598 | 0.83 | TDO2 (0.42) | KIF11TDO2KDM4EMAPTGABRA1 | |
| SCHEMBL32691812 | 0.81 | TDO2 (0.51) | KIF11TDO2KDM4EMAPTGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 530 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129429-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2025-04-24 | — | — | US | claimed |
| US-20250032624-A1 | SMALL MOLECULE DEGRADATION METHODS FOR TREATING ALS/FTD | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-01-30 | — | — | US | claimed |
| EP-4423302-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | Foundation Medicine, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| EP-4422627-A1 | SMALL MOLECULE DEGRADATION METHODS FOR TREATING ALS/FTD | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-09-04 | — | — | EP | claimed |
| CN-118414439-A | Novel kinase fusion by liquid biopsy | 基金会医学公司 | 2024-07-30 | — | — | CN | claimed |
| EP-4399330-A1 | GENE FUSIONS IN SARCOMA | Foundation Medicine, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| CN-118159268-A | Small molecule degradation method for treating ALS/FTD | 佛罗里达大学研究基金公司 | 2024-06-07 | — | — | CN | claimed |
| US-20230381170-A1 | METHOD FOR TREATING ALS/FTD THROUGH DEGRADATION OF RNA REPEAT EXPANSION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-30 | — | — | US | claimed |
| US-20230373929-A1 | FUSED RING DIIMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | XIANGBEI WELMAN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | claimed |
| EP-4215521-A1 | FUSED RING DIIMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Xiangbei Welman Pharmaceutical Co., Ltd (CN) | 2023-07-26 | — | — | EP | claimed |
| EP-1663219-A2 | USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023255-A2 | USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-03-17 | — | — | WO | claimed |
| EP-1468007-A2 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | Human Genetic Signatures PTY Ltd. (AU) | 2004-10-20 | — | — | EP | claimed |
| WO-2003051901-A2 | PSEUDONUCLEOTIDE COMPRISING AN INTERCALATOR | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2003-06-26 | — | — | WO | claimed |
| JP-2003506394-A | — | — | 2003-02-18 | — | — | JP | claimed |
| EP-1246605-A2 | FACILITATING THE PRESERVATION OF SIGHT BY INCREASING OPTIC NERVE, CHOROIDAL AND RETINAL BLOOD FLOW | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-10-09 | — | — | EP | claimed |
| WO-2001010406-A2 | FACILITATING THE PRESERVATION OF SIGHT BY INCREASING OPTIC NERVE, CHOROIDAL AND RETINAL BLOOD FLOW | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2001-02-15 | — | — | WO | claimed |
| WO-1986007057-A1 | METHYL DERIVATIVES OF METHYLATED BIS 7H PYRIDOCARBAZOLES AND FARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1986-12-04 | — | — | WO | claimed |
| EP-0008556-B1 | BIS 7H PYRIDOCARBAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ANVAR Agence Nationale de Valorisation de la Recherche (FR) | 1984-01-25 | — | — | EP | claimed |
| EP-0008556-A1 | Bis 7H pyridocarbazole derivatives and pharmaceutical compositions containing them | ANVAR Agence Nationale de Valorisation de la Recherche (FR) | 1980-03-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381170-A1 | METHOD FOR TREATING ALS/FTD THROUGH DEGRADATION OF RNA REPEAT EXPANSION | RBM39, HNRNPC, HNRNPH3 | KIF11 1748/4885TDO2 4532/4885KDM4E 880/4885 |
| US-20250032624-A1 | SMALL MOLECULE DEGRADATION METHODS FOR TREATING ALS/FTD | SNRPE, HNRNPC, RBM39 | KIF11 1513/4885TDO2 4647/4885KDM4E 1083/4885 |
| US-20230373929-A1 | FUSED RING DIIMIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | WEE1, CYP51A1, WEE2 | KIF11 557/4885TDO2 2577/4885KDM4E 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.